Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy
| Autor: | Eny Maria Goloni-Bertollo, José Victor Maniglia, Érika Cristina Pavarino, Gabriela Helena Rodrigues-Fleming, Mauricio Pereira Maniglia, Anelise Russo, Juliana Garcia de Oliveira-Cucolo, Patrícia Matos Biselli-Chicote |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Male medicine.medical_treatment GSTP1 0302 clinical medicine Risk Factors Antineoplastic Combined Chemotherapy Protocols glutathione transferase genetic polymorphism Chemotherapy agents Aged 80 and over biology General Medicine Chemoradiotherapy Middle Aged Prognosis Primary tumor Glutathione S-transferase 030220 oncology & carcinogenesis Female Fluorouracil Research Article Adult medicine.medical_specialty 03 medical and health sciences head and neck neoplasms Internal medicine medicine Biomarkers Tumor Humans Genetic Predisposition to Disease Aged Retrospective Studies Polymorphism Genetic business.industry Squamous Cell Carcinoma of Head and Neck Head and neck cancer Haplotype Cancer medicine.disease Head and neck squamous-cell carcinoma Radiation therapy 030104 developmental biology Methotrexate Glutathione S-Transferase pi Haplotypes biology.protein Cisplatin business Follow-Up Studies |
| Zdroj: | Asian Pacific Journal of Cancer Prevention : APJCP |
| ISSN: | 2476-762X |
| Popis: | Background/aim The Glutathione S-transferases (GSTs) are important carcinogen-metabolizing enzymes. Polymorphisms involved in these enzymes can modulate the development and treatment of head and neck cancer. To investigate the association of GSTs polymorphisms with head and neck cancer and risk factors, clinical-pathological features, and survival time of the patients treated with chemotherapy and/or radiotherapy. Methods The GST gene polymorphisms were evaluated in 197 cases and 514 controls by PCR-RFLP-Polymerase Chain Reaction Restriction Fragment Length Polymorphism. Results The GSTP-313 was associated with a decreased risk for HNSCC (p=0.050). The GSTP1 haplotype analysis revealed a higher frequency of the AC and AT haplotypes in the case group than in the control group (p=0.013 and p=0.019, respectively), and the opposite for G-C haplotype (p = 0.015). Yet, the different combinations between the genotypes were associated with an increased risk of cancer. The study showed no association between the polymorphisms and primary tumor site, clinical-pathological characteristics, treatment (chemotherapy and/or radiotherapy) and survival time of the patients. Conclusion The GST polymorphisms combination showed an increased risk for carcinogenesis, and studies with larger casuistry can contribute to the clarification of the role in individual patient differences for the response to chemotherapy and/or radiotherapy and identify biomarkers of susceptibility. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|